文献速递术前评估与围术期医学疼痛医学

围术期加巴喷丁类药物的利弊辩论: nuanced 方法最佳

Pro-con debate on perioperative gabapentinoids: a nuanced approach is the best one.
PubMed 文献 · Reg Anesth Pain Med · 2025-11-05

本文以正反辩论形式讨论2025年围术期使用加巴喷丁类药物的利弊。加巴喷丁和普瑞巴林虽能减轻疼痛和阿片类药物消耗,但中枢神经系统不良反应(头晕、镇静)明确,与阿片类联用可协同导致呼吸抑制,长期使用可能认知缺陷,最终主张个体化 nuanced 方法。

要点

  • 加巴喷丁类用于急性围术期疼痛仍属超说明书用药。
  • 中枢不良反应(头晕、镇静)在老年人中尤其成问题。
  • 与阿片类联用可协同导致呼吸抑制,长期使用可能认知缺陷。

核心结论

  • 围术期加巴喷丁类药物的使用应基于个体患者进行细致权衡,而非一刀切。

研究设计与样本

  • 本文为针对围术期加巴喷丁类药物的正反辩论,基于已发表证据阐述立场。

主要发现

  • 加巴喷丁类具有可预测的药代动力学,是少数治疗神经病理性疼痛的药物类别之一,且有大量文献支持其减轻疼痛和阿片类药物消耗的能力。
  • 中枢神经系统不良反应包括头晕和镇静已明确,在老年人中尤其成问题。
  • 与阿片类药物联用可协同导致呼吸抑制,长期使用可能认知缺陷。

临床怎么用

  • 围术期医师应重新考虑将加巴喷丁类纳入加速康复及其他围术期方案,并基于个体患者情况决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the age of the opioid epidemic and a widespread desire to reduce opioid prescriptions, both in outpatient practices and hospitals, we have welcomed non-opioid medications as one possible strategy to reduce the reliance on opioids for the treatment of pain. For anesthesiologists, surgeons, and other perioperative physicians, minimizing exposure to opioids in the perioperative period has been a focal point for several decades now and countless protocols have been described, adopted, and studied. Gabapentin and pregabalin, known collectively as gabapentinoids, have been included in many of these protocols and it is not difficult to see why. They have predictable pharmacokinetics, are one of the only medication classes to treat neuropathic pain, and have sizeable literature support for their ability to reduce pain and opioid consumption. Their use for acute perioperative pain remains off-label. As with many drugs, we have learned more over time and now have a fuller picture of the benefits and risks associated with gabapentinoids. In particular, the central nervous system adverse effects, including dizziness and sedation, are now well established and can be especially problematic in the elderly. Synergistic respiratory depression when combined with opioids and even possible cognitive deficits from prolonged use have been described, forcing some perioperative physicians to rethink their inclusion in enhanced recovery and other perioperative protocols. In this pro-con discussion, we debate the merits of perioperative gabapentinoids in 2025, relying on published evidence for our positions, and ultimately call for a nuanced approach that considers the individual patient before us.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Gandhi K, Schwenk ES. Pro-con debate on perioperative gabapentinoids: a nuanced approach is the best one. Reg Anesth Pain Med. 2025. PMID: 41193386. doi:10.1136/rapm-2025-107210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。